Skip to main content
Equibles

SNY · Sanofi · Metrics

Track SNY — free

Use SNY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SNY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$39.91 +0.35 (+0.88%)
Rebalance outlook locked
Market Cap
$98.51B
Shares
2.40B
Volume · Oct 6 3.05M Avg daily vol (3M) 2.88M

SNY metrics

49 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$39.56
Market cap
$98.51B

Price action

20 metrics
Price change (1W)
-4.1%
Price change (30D)
-8.4%
Price change (3M)
-7.3%
Price change (6M)
-17.0%
Price change (YTD)
-18.5%
Price change (1Y)
-22.4%
Trailing year
Price change (5Y)
-18.2%
52-week high
$52.34
52-week low
$39.51
Change from 52-week high
-24.5%
Change from 52-week low
+0.0%
Annualized volatility
23.2%
Annualized volatility (3M)
20.9%
Beta
0.3
RSI (14D)
26.7
Price vs SMA 50
-8.8%
Price vs SMA 200
-12.2%
Avg volume (3M)
2.91M
Relative volume
1.3
Average dollar volume
$125.71M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - General
Shares outstanding
2.40B

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.2
reciprocal yield 85.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-10-30
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
77.2%
Operating margin
14.5%
Trailing 12 months
Net margin
17.9%
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+6.2%
Year over year
Net income growth YoY
+40.5%
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-2.4%
Year over year · fewer shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
10.9%
Return on assets
6.2%
Debt / equity
0.3
Current ratio
1.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$12.83B
Latest balance sheet
Cash & equivalents
$8.99B
Total assets
$148.82B
Total debt
$21.82B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
723
13F filer change QoQ
-29
Institutional ownership
8.1%

Short interest

3 metrics
Short interest
0.4%
Latest settlement · 4.3 days to cover
Days to cover
4.3d
Short-squeeze score
40 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1121404 CUSIP 80105N105 13F (30d) 17 filings 15 filers Visit website Investor relations